Eosinophilia in Patients with Asthma: A Sign of Eosinophilic Granulomatosis with Polyangiitis (EGPA)?

To participate in this activity, please start here:

Welcome to this video question and answer interview with Michael Wechsler, MD. In this activity, Dr. Wechsler answers common questions physicians have about the diagnosis, prognosis, and treatment of EGPA. This Q&A addresses topics such as the role of ANCA in diagnosis and prognosis, the clinical signs and symptoms of EGPA, clinical features associated with poor prognosis, specialists who may see patients with EGPA presenting as another disorder, and treatment response, escalation, and monitoring.

Want to learn more?
Visit Part 1 of this two-part educational series to get answers to frequently asked questions.

Course Credit:

0.75 AANP Contact Hour
0.75 AMA PRA Category 1 CreditTM

Dates:

Opens: 2020-06-30
Closes: 2021-06-30

Target Audience:

This activity was developed for allergist/immunologists, rheumatologists, pulmonologists, hematologists, dermatologists, cardiologists, EENT specialists and other clinicians involved in the care of patients with EGPA.

This educational activity is supported by an educational grant from GlaxoSmithKline.
  • Michael Wechsler, MD

    Professor of Medicine
    Director, NJH Cohen Family Asthma Institute
    Department of Medicine
    National Jewish Health
    Denver, Colorado

Learning Objectives

  • Discuss the clinical signs and symptoms that support a diagnosis of EGPA
  • Describe the clinical progression of EGPA
  • Classify patients’ risk based on disease activity and the presence of ANCA
  • Select an appropriate therapy for EGPA based on patient’s disease activity and characteristics

Faculty Disclosures

Michael Wechsler, MD

Consultant                   

  • AstraZeneca – clinical area: Asthma/EGPA
  • Equillium – clinical area: Asthma
  • Genentech – clinical area: Asthma
  • Genzyme – clinical area: Asthma
  • GlaxoSmithKline – clinical area: Asthma/EGPA
  • Regeneron – clinical area: Asthma
  • Restorbio – clinical area: Asthma
  • Sanofi – clinical area: Asthma
  • Teva – clinical area: Asthma

Speakers bureau 

  • AstraZeneca – clinical area: Asthma/EGPA
  • GlaxoSmithKline – clinical area: Asthma/EGPA
  • Sanofi – clinical area: Asthma

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.
This program is designated for up to 0.75 contact hour. Program ID# 5825-EM.

Additional Content Planners

Juan Cardet, MD (Peer Reviewer)
No significant relationships to disclose.

Chris Fischer, MSc (Medical Writer)
No significant relationships to disclose.

Heather M. Jimenez, FNP-C (Nurse Planner)
No significant relationships to disclose.

Annenberg Center for Health Sciences

All staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.